---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-032935"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T19:57:25.528520+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vistagen completes PALISADE-4 Phase 3 patient visits; topline data due Q2 2026

## Summary
- Last patient completed randomized portion of Phase 3 trial for fasedienol acute treatment of social anxiety disorder.
- Topline results for PALISADE-4 expected in second quarter 2026.
- FDA has no comments on refined statistical analysis plan incorporating pre-dose SUDS baseline covariate.
- Open-label extension remains ongoing; fasedienol has FDA Fast Track designation.

## SEC filing metadata
- accession: 0001628280-26-032935
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828026032935/0001628280-26-032935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828026032935/vtgn-20260508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-032935
- JSON: https://secwatch.observer/filing/0001628280-26-032935.json
- Plain text: https://secwatch.observer/filing/0001628280-26-032935.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.